Loading…
Actinium Pharmaceuticals, Inc. is projected to rise to $0.9749 by 2027, a +5% move from its current price of $0.93. ATNM is currently trading below its 50-day average (a bearish sign). Technical indicators currently lean strong sell.
A data-driven summary — not financial advice. See the full breakdown below.
Live market data via Yahoo Finance · updated 7/11/2026
| Period | Min | Prediction | Max | Change |
|---|---|---|---|---|
| Jul 13 | $0.8997 | $0.9302 | $0.9618 | +0.03% |
| Jul 14 | $0.8876 | $0.9305 | $0.9755 | +0.05% |
| Jul 15 | $0.8784 | $0.9307 | $0.9861 | +0.08% |
| Jul 16 | $0.8708 | $0.931 | $0.9952 | +0.10% |
| Jul 17 | $0.8642 | $0.9312 | $1.00 | +0.13% |
| Jul 18 | $0.8583 | $0.9314 | $1.01 | +0.15% |
| Jul 19 | $0.8529 | $0.9317 | $1.02 | +0.18% |
| Period | Min | Prediction | Max | Change |
|---|---|---|---|---|
| Week 1 | $0.8529 | $0.9317 | $1.02 | +0.18% |
| Week 2 | $0.8237 | $0.9333 | $1.06 | +0.36% |
| Week 3 | $0.8024 | $0.935 | $1.09 | +0.54% |
| Week 4 | $0.785 | $0.9367 | $1.12 | +0.72% |
| Week 5 | $0.7702 | $0.9383 | $1.14 | +0.90% |
| Week 6 | $0.7571 | $0.94 | $1.17 | +1.08% |
| Week 7 | $0.7455 | $0.9417 | $1.19 | +1.26% |
Short-term targets derived from the forecast trend and recent volatility. Highly uncertain — not financial advice.
Actinium Pharmaceuticals, Inc. develops antibody radiation conjugates and other targeted radiotherapies intended to improve outcomes for people who have failed existing oncology therapies. The company offers Actimab-A, a CD33 targeting radiotherapeutic for patients with Relapsed/Refractory AML which is in to a Phase 2/3 Trial; and Iomab-ACT, to improve patient access to and outcomes with cellular therapies, such as CAR-T and gene therapies for non-malignant hematologic disorders such as sickle cell disease.
It also develops ATNM-400, a antibody radioconjugate that deliver alpha-emitter Ac-225 to prostate cancer cells. In addition, the company's Iomab-B is an induction and conditioning agent prior to bone marrow transplant in patients with relapsed and refractory acute myeloid leukemia. Further, it engages with the National Cancer Institute under the cooperative research and development agreement for the development of Actimab-A in AML and other myeloid malignancies, and its research and development activities primarily focus on advancing various preclinical programs for solid tumor indications.
The company is based in New York, New York.
Actinium Pharmaceuticals, Inc. (ATNM) is a Healthcare stock currently trading at $1.00 with a market cap of $31.37M, and ranked 4744. The stock’s near-term technical picture is BEARISH, with RSI14 at 40 and the price below the SMA50 and SMA200 (SMA50 is $1.19 and SMA200 is $1.33).
The 30-day range runs from $0.8061 to $1.24, with a near-term resistance at $1.34 and support at $1.00. Forecasts depict a path from NEUTRAL in 2026 toward BULLISH in later years, with 2026 avg $1.00 and ROI 0, rising to 2030 avg $1.10 and ROI 10.3, and reaching 2050 avg $3.75 with ROI 275.1. In between, 2032–2035 show stronger upside (2032 avg $1.54 with ROI 53.9; 2033 avg $1.59 with ROI 59; 2034 avg $1.55 with ROI 55; 2035 avg $1.58 with ROI 57.8), and the trajectory continues to 2040 avg $2.36 with ROI 136.5, then to 2050 avg $3.75 with ROI 275.1.
A major floor 23.7% below — a decisive break under it would weaken the trend.
Price is testing support right now (0.0% away) — a key level to hold.
The nearest ceiling, 35.5% above — a clean break opens room to run.
A major ceiling 63.4% above — clearing it would confirm fresh momentum.
Key ATNM support and resistance from recent price action — levels where the trend has historically paused or reversed. Percentages are the distance from the current price.
A snapshot of ATNM market posture derived from its technical indicators and recent volatility. Higher trend and alignment lean bullish; higher risk means larger swings.
Technical Analysis
Indicators computed on daily closing prices.
| Period | SMA | Action | EMA | Action |
|---|---|---|---|---|
| MA 5 | $0.9762 | Sell | $0.9658 | Sell |
| MA 10 | $0.9802 | Sell | $0.9792 | Sell |
| MA 20 | $0.9946 | Sell | $1.01 | Sell |
| MA 50 | $1.11 | Sell | $1.07 | Sell |
| MA 100 | $1.13 | Sell | $1.14 | Sell |
| MA 200 | $1.27 | Sell | $1.28 | Sell |
| Name | Value | Action |
|---|---|---|
| RSI (14) | 37.86 | Neutral |
| Stoch RSI (14) | 23.81 | Neutral |
| CCI (20) | -166.54 | Sell |
| Williams %R (14) | -100.00 | Info |
| MACD (12,26,9) | 0.00 | Buy |
| ROC (12) | -8.82 | Sell |
| Bollinger %B (20,2) | -0.03 | Buy |
| Stochastic %K (14) | 0.00 | Buy |
| TRIX (15) | -0.60 | Sell |
| Awesome (5,34) | -0.08 | Sell |
| Ultimate (7,14,28) | 37.05 | Neutral |
| Momentum (10) | -0.02 | Sell |
| Aroon Osc (25) | -100.00 | Sell |
| Hull MA (9) | 0.97 | Sell |
| ADX (14) | 18.86 | Neutral |
| ATR (14) | 0.03 | Info |
The 30-day technical picture is BEARISH, with RSI14 at 40. The stock trades with a bearish tilt and sits below key averages, with SMA50 at $1.19 and SMA200 at $1.33. The near-term picture shows support at $1.00 and resistance at $1.34, while the 30-day range spans from $0.8061 to $1.24.
| Year | Min | Avg | Max | ROI | Sentiment |
|---|---|---|---|---|---|
| $0.93 | $0.93 | $1.20 | 0% | Neutral | |
| $0.76 | $0.9749 | $1.33 | +5% | Neutral | |
| $0.6891 | $0.9153 | $1.31 | -2% | Neutral | |
| $0.7099 | $0.9708 | $1.43 | +4% | Neutral | |
| $0.7147 | $1.00 | $1.52 | +8% | Neutral | |
| $0.7702 | $1.11 | $1.72 | +19% | Neutral | |
| $0.9155 | $1.35 | $2.14 | +45% | Bullish | |
| $0.9583 | $1.44 | $2.34 | +55% | Bullish | |
| $0.9605 | $1.47 | $2.43 | +58% | Bullish | |
| $0.8897 | $1.39 | $2.34 | +49% | Bullish | |
| $1.27 | $2.16 | $3.90 | +132% | Bullish | |
| $1.64 | $3.28 | $6.56 | +252% | Bullish |
Current year — the forecast is anchored to the live price, so ROI shows 0%.
| Month | Min | Avg | Max | Change |
|---|---|---|---|---|
| July 2026 | $0.93 | $0.93 | $1.12 | +0.00% |
| August 2026 | $0.7769 | $0.9227 | $1.13 | -0.79% |
| September 2026 | $0.7946 | $0.9519 | $1.18 | +3.17% |
| October 2026 | $0.8182 | $0.9874 | $1.24 | +3.73% |
| November 2026 | $0.7966 | $0.9673 | $1.22 | -2.03% |
| December 2026 | $0.7712 | $0.942 | $1.20 | -2.62% |
Click any year to see its month-by-month ATNM forecast. Min / Avg / Max are a bear / base / bull scenario; ROI is the projected move from the current price. Change is the month-over-month move in the average. Estimates, not guarantees.
In 2026, ATNM is projected to trade between $0.93 and $1.20, averaging $0.93 — a potential gain of 0% from today's $0.93. A consolidation phase looks the most probable path here.
Actinium Pharmaceuticals, Inc.'s 2027 outlook centres on $0.9749, within a $0.76 to $1.33 range. That is up +5% on the projected 2026 average. That marks a +5% change versus current levels. Price action looks broadly range-bound.
By 2028, ATNM could reach as high as $1.31, with a base case around $0.9153 and support toward $0.6891 — roughly -2% from $0.93. A consolidation phase looks the most probable path here.
Expect ATNM to range from $0.7099 to $1.43 through 2029. The $0.9708 average target implies a +4% move from current prices. That is up +6% on the projected 2028 average. Price action looks broadly range-bound.
The ATNM price prediction for 2030 points to an average of $1.00 (low $0.7147, high $1.52) — a potential gain of +8% on today's $0.93. A consolidation phase looks the most probable path here.
In 2031, ATNM is projected to trade between $0.7702 and $1.72, averaging $1.11 — a potential gain of +19% from today's $0.93. That is up +10% on the projected 2030 average. Price action looks broadly range-bound.
Actinium Pharmaceuticals, Inc.'s 2032 outlook centres on $1.35, within a $0.9155 to $2.14 range. That is up +22% on the projected 2031 average. That marks a +45% change versus current levels. Buyers look set to stay in control over this stretch.
By 2033, ATNM could reach as high as $2.34, with a base case around $1.44 and support toward $0.9583 — roughly +55% from $0.93. Momentum favours further upside here.
Expect ATNM to range from $0.9605 to $2.43 through 2034. The $1.47 average target implies a +58% move from current prices. That is up +2% on the projected 2033 average. Buyers look set to stay in control over this stretch.
The ATNM price prediction for 2035 points to an average of $1.39 (low $0.8897, high $2.34) — a potential gain of +49% on today's $0.93. Momentum favours further upside here.
In 2040, ATNM is projected to trade between $1.27 and $3.90, averaging $2.16 — a potential gain of +132% from today's $0.93. That is up +56% on the projected 2035 average. Buyers look set to stay in control over this stretch.
Actinium Pharmaceuticals, Inc.'s 2050 outlook centres on $3.28, within a $1.64 to $6.56 range. That is up +52% on the projected 2040 average. That marks a +252% change versus current levels. Momentum favours further upside here.
Investing $1,000 in ATNM today (≈ 1,075.268817 ATNM) could be worth
$3,522.59
+$2,522.59 (+252%) by 2050 · US Dollar
Based on the average projected ATNM price of $3.28 in 2050.
Based on the base (average) forecast scenario. FX rates are indicative. Estimates only — not financial advice.
See what a past investment in ATNMwould be worth at today's price.
$1,000 invested in ATNM on Jul 10, 2025 (≈ 645.16131 ATNM) would be worth
$600
-$400 (-40.0%) today · 0.60× · US Dollar
Based on a ATNM entry price of $1.55 vs. today's $0.93.
| Invested | Entry price | Value today | Return |
|---|---|---|---|
| 1 week ago | $0.981 | $948.01 | -5.2% |
| 1 month ago | $1.05 | $885.71 | -11.4% |
| 3 months ago | $1.08 | $861.11 | -13.9% |
| 6 months ago | $1.3 | $715.38 | -28.5% |
| 1 year ago | $1.55 | $600 | -40.0% |
| All time (5.0y) ago | $6.98 | $133.24 | -86.7% |
Past performance from historical market data — it does not predict future results. FX rates are indicative. Not financial advice.
Enter a price to see how it sits against our ATNM forecast.
Our base-case forecast reaches $1.90 around 2040.
Implied market cap at $1.90: $59.61M
The multi-year forecast outlines a shift from NEUTRAL to BULLISH sentiment starting in 2032, with notable upside in the latter years. In 2030 the avg price is projected at $1.10 with ROI 10.3, and by 2040 the avg price is $2.36 with ROI 136.5, culminating in 2050 with an avg price of $3.75 and ROI 275.1. The sequence also shows intermediate bulls: 2032 avg $1.54 ROI 53.9 and 2033 avg $1.59 ROI 59, followed by 2034 avg $1.55 ROI 55 and 2035 avg $1.58 ROI 57.8.
Early years remain NEUTRAL (2026–2031), including 2026 avg $1.00 ROI 0 and 2027 avg $1.05 ROI 5.5, with 2028 avg $0.975 ROI -2.5, 2029 avg $1.09 ROI 8.9, 2030 avg $1.10 ROI 10.3, and 2031 avg $1.19 ROI 18.9. These figures are estimates and carry inherent uncertainty.
Tap a question to reveal the answer.
2030 min $0.7882, avg $1.10, max $1.67, ROI 10.3.
Forecasts show NEUTRAL for 2026–2031 and BULLISH from 2032 onward; the 2032 avg is $1.54 with ROI 53.9, and 2050 avg is $3.75 with ROI 275.1.
Yes, the max forecast reaches $4.25 in 2040 and $7.45 in 2050.
The 30-day range is $0.8061 to $1.24.
Current price $1.00; market cap $31.37M.
Actinium Pharmaceuticals, Inc. Community Discussion
0Share your Actinium Pharmaceuticals, Inc. price prediction and read what the community thinks. Be respectful — comments are public and not financial advice.
Be the first to share your prediction…
What's your take? Add a comment above to start the conversation.